OPTN News and Press, OptiNose Inc. From 05/09/21

The following slide deck was published by OptiNose, Inc. in conjunction with their 2021 Q1 earnings call. For further details see: OptiNose, Inc. 2021 Q1 - Results - Earnings Call Presentation

OptiNose, Inc. (OPTN) Q1 2021 Earnings Conference Call May 5, 2021, 8:00 AM ET Company Participants Jonathan Neely - VP, IR & Business Operations Keith Goldan - Chief Financial Officer Peter Miller - Chief Executive Officer Ramy Mahmoud - President and Chief Operating Officer Victor Clave...

OptiNose (OPTN): Q1 GAAP EPS of -$0.49 beats by $0.03.Revenue of $11.96M (+69.4% Y/Y) beats by $0.76M.Press Release For further details see: OptiNose EPS beats by $0.03, beats on revenue

Company reports first quarter total revenue of $12.0 million First quarter 2021 XHANCE net revenue of $11.0 million increased 55% compared to first quarter 2020 Conference call and webcast to be held today at 8:00 a.m. Eastern Time YARDLEY, Pa., May 05, 2021 (GLOBE...

Conference Call and Webcast to be held May 5, 2021 at 8:00 a.m. Eastern Time Company to Present at the RBC Capital Markets Global Healthcare Conference on May 18, 2021 YARDLEY, Pa., April 28, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company foc...

New Harris Survey Reveals Chronic Nasal Congestion Is Surprisingly Widespread: Nearly 1 in 4 Americans With Nasal Congestion Experience Symptoms Almost Every Day Sufferers often confused on the cause of symptoms and should "go deeper" because nasal polyps are often undiagnosed ...

YARDLEY, Pa., April 12, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business upd...

OptiNose's XHANCE net sales showed good traction in FY2020 despite the considerable headwinds from the COVID-19 pandemic. With two Phase 3b trials set in the near future for another XHANCE indication, a novel exhalation delivery system, and trading at 2.5x 2021E net revenue, OptiNose ...

OptiNose, Inc. (OPTN) Q4 2020 Earnings Conference Call March 3, 2021 8:00 AM ET Company Participants Jonathan Neely – Vice President-Investor Relations Peter Miller – Chief Executive Officer Keith Goldan – Chief Financial Officer Ramy Mahmoud – President and Chief ...

Ovid Therapeutics (OVID) +73% after soticlestat deal with Takeda.KemPharm (KMPH) +69% on FDA approval of ADHD drug.Ocugen, Inc. (OCGN) +39% on Indian partner’s COVID-19 vaccine efficacy data.Asensus Surgical (TRXC) +33% on FDA clearance for Senhance Surgical System....